Your Article Summary
See Latest ArticlesOutcomes of patients with stage III non-small cell lung cancer treated with chemotherapy and radiation with and without surgery
Cancer, 06/26/09
Caglar HB et al. - In a study to identify the factors associated with improved outcome after treatment for stage III non-small cell lung cancer (NSCLC), it seems that stage at the time of treatment (stage IIIA vs stage IIIB) and use of surgery were the only factors associated with improved outcome.
Methods- A retrospective review of stage III NSCLC pts was done.
- Pts were followed for toxicity, local and distant failure, and overall survival (OS).
- Multivariate Cox logistic regression analysis was used to determine factors associated with treatment outcome.
- 144 pts received concurrent chemoradiation (CRT) for stage III NSCLC.
- 80 of 144 pts were men (56%), and median age was 61 yrs.
- 62 pts (43%) had stage IIIA NSCLC, and 82 pts (57%) had stage IIIB NSCLC.
- Radiotherapy (RT) was given concurrently with chemotherapy to all pts; 100 pts (69%) received CRT without surgery, and 44 pts (31%) received with neoadjuvant CRT followed by surgical resection.
- Median RT dose was 60 grays (Gy).
- Median follow-up was 15 mos, median potential follow-up was 37 mos, and median OS was 22 mos.
- 1-yr and 2-yr survival rates were 68% and 47%, respectively.
- Among the 44 pts who underwent resection, median survival was 61 mos, and 2-yr survival rate was 73%.
- On multivariate analysis, stage at the time of treatment (stage IIIA vs stage IIIB) and use of surgery were the only factors associated with improved outcome.
Today in Diagnostics/Radiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Hodgkin's lymphoma in remission after first-line therapy: Which patients need FDG-PET/CT for follow-up?
Annals of Oncology, 11/17/09
Ovarian cancer screening and early detection
Women's Health, 11/04/09
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
Lung Cancer, 11/03/09
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
The Lancet Oncology, 11/02/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09